N,N-二癸基-N-甲基-1-癸烷氯化铵 | 5137-56-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N,N-二癸基-N-甲基-1-癸烷氯化铵
• 英文名称: methyl-tri-(decyl)-ammonium chloride
• 英文别名: 1-Decanaminium, N,N-didecyl-N-methyl-, chloride；tris-decyl(methyl)azanium;chloride
• CAS: 5137-56-4
• 化学式: C₃₁H₆₆N*Cl
• 分子量: 488.325
• InChiKey: UMMDBKGUDMBUSR-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  7.86
• 重原子数：
  33
• 可旋转键数：
  27
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N,N-二癸基-N-甲基-1-癸烷氯化铵 、 硬脂酸 以100%的产率得到
  参考文献：
  名称：

  BHATI, A.;HAMILTON, R. J.;STEVEN, D. A.;ANEJA, R.;PADLEY, F. B., J. CHEM. SOC. PERKIN TRANS., 1983, N 10, 1553-1558

  摘要：

  DOI：

文献信息

• [EN] SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME<br/>[FR] INTERMÉDIAIRE SYNTHÉTIQUE D'UN COMPOSÉ OXAZOLE ET PROCÉDÉ DE PRODUCTION ASSOCIÉ
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2011093529A1

  公开（公告）日：2011-08-04

  An object of the present invention is to provide a method for producing an oxazole compound in a high yield. The object can be achieved by a compound represented by Formula (11): wherein R1 is a hydrogen atom or lower-alkyl group; R2 is a 1-piperidyl group substituted at the 4-position with a substituent selected from (A1a) a phenoxy group substituted on the phenyl moiety with one or more halogen-substituted lower-alkoxy groups, (A1b) a phenoxy-substituted lower-alkyl group substituted on the phenyl moiety with one or more halogen-substituted lower-alkyl groups, (A1c) a phenyl-substituted lower-alkoxy lower-alkyl group substituted on the phenyl moiety with halogen, (A1d) a phenyl-substituted lower-alkyl group substituted on the phenyl moiety with one or more halogen-substituted lower-alkoxy groups, (A1e) an amino group substituted with a phenyl group substituted with one or more halogen-substituted lower-alkoxy groups, and a lower-alkyl group, and (A1f) a phenyl-substituted lower-alkoxy group substituted on the phenyl moiety with one or more halogen-substituted lower-alkoxy groups; n is an integer from 1 to 6; and X3 is an organic sulfonyloxy group.

  本发明的目的是提供一种高产率生产噁唑化合物的方法。该目的可以通过由式（11）表示的化合物实现：其中R1是氢原子或较低的烷基基团；R2是在4-位被取代的1-哌啶基团，所述取代基选自（A1a）苯氧基在苯基上取代一个或多个卤素取代的较低烷氧基团，（A1b）苯氧基取代的较低烷基基团在苯基上取代一个或多个卤素取代的较低烷基基团，（A1c）苯基取代的较低烷氧基较低烷基基团在苯基上取代卤素，（A1d）苯基取代的较低烷基基团在苯基上取代一个或多个卤素取代的较低烷氧基团，（A1e）氨基取代的苯基取代一个或多个卤素取代的较低烷氧基团和较低烷基基团，以及（A1f）苯基取代的较低烷氧基团在苯基上取代一个或多个卤素取代的较低烷氧基团；n是1到6之间的整数；X3是有机磺酰氧基团。
• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。
• NEW PROCESS FOR PREPARATION OF ATOVAQUONE AND NOVEL INTERMEDIATES THEREOF
  申请人：Kumar Ashok

  公开号：US20100081847A1

  公开（公告）日：2010-04-01

  Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as “Form IPCA-ATO,” and the preparation thereof.

  本文披露了一种用于制备阿托伐醌的新型工艺。该工艺包括将1,4-萘醌与反式-4-(4-氯苯基)环己烷羧酸反应，然后进行卤化以获得二卤化合物。此外，二卤化合物的脱卤化产生单卤化合物，经水解生成阿托伐醌。该发明还披露了一种名为“Form IPCA-ATO”的高度纯净和明确定义的多晶形态的阿托伐醌，以及其制备方法。
• Highly Pure Paliperidone or a Pharmaceutically Acceptable Salt Thereof Substantially Free of Keto Impurity
  申请人：Bapat Uday Rajaram

  公开号：US20090247553A1

  公开（公告）日：2009-10-01

  Provided herein is a highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4,9-dione, a process for the preparation thereof, and pharmaceutical compositions comprising highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity.

  本文提供了一种高纯度的帕利哌酮或其在很大程度上不含酮杂质的药用盐，化学名称为3-[2-[4-(6-氟-1,2-苯并异噁唑-3-基)-1-哌啶基]乙基]-2-甲基-7,8-二氢-6H-吡啶并[1,2-a]嘧啶-4,9-二酮，以及其制备方法和包含高纯度帕利哌酮或其在很大程度上不含酮杂质的药用盐的药物组合物。
• SOLID STATE FORMS OF PALIPERIDONE SALTS AND PROCESS FOR THE PREPARATION THEREOF
  申请人：Dixit Girish

  公开号：US20120100188A1

  公开（公告）日：2012-04-26

  Provided herein are solid state forms of paliperidone salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. Paliperidone is represented by the following structural formula (I): More particularly, provided are solid state forms of paliperidone acid addition salts, wherein the acid counter ion is provided by an acid selected from the group consisting of L-(+)-tartaric acid, p-toluenesulfonic acid, maleic acid, oxalic acid, fumaric acid, acetic acid and malic acid. Provided also herein is a process for preparing substantially pure paliperidone free base using the solid state forms of paliperidone salts.

  本文提供了帕利哌酮盐的固态形式，制备方法，药物组合物以及治疗方法。帕利哌酮的结构式如下（I）：更具体地，提供了帕利哌酮酸加合物盐的固态形式，其中酸对离子由L-(+)-酒石酸、对甲苯磺酸、马来酸、草酸、富马酸、乙酸和苹果酸等酸中选择提供。本文还提供了一种利用帕利哌酮盐的固态形式制备基本纯净的帕利哌酮游离碱的方法。